Cargando…

One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a

BACKGROUND: COVID-19 has spread rapidly around the world, affecting a large percentage of the population. When lifting certain mandatory measures for an economic restart, robust surveillance must be established and implemented, with nucleic acid detection for SARS-CoV-2 as an essential component. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yangyang, Yu, Lei, Liu, Chengxi, Ye, Shanting, Chen, Wei, Li, Dechang, Huang, Weiren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884969/
https://www.ncbi.nlm.nih.gov/pubmed/33593370
http://dx.doi.org/10.1186/s12967-021-02741-5
_version_ 1783651526322946048
author Sun, Yangyang
Yu, Lei
Liu, Chengxi
Ye, Shanting
Chen, Wei
Li, Dechang
Huang, Weiren
author_facet Sun, Yangyang
Yu, Lei
Liu, Chengxi
Ye, Shanting
Chen, Wei
Li, Dechang
Huang, Weiren
author_sort Sun, Yangyang
collection PubMed
description BACKGROUND: COVID-19 has spread rapidly around the world, affecting a large percentage of the population. When lifting certain mandatory measures for an economic restart, robust surveillance must be established and implemented, with nucleic acid detection for SARS-CoV-2 as an essential component. METHODS: We tried to develop a one-tube detection platform based on RT-RPA (Reverse Transcription and Recombinase Polymerase Isothermal Amplification) and DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR) technology, termed OR-DETECTR, to detect SARS-CoV-2. We designed RT-RPA primers of the RdRp and N genes following the SARS-CoV-2 gene sequence. We optimized reaction components so that the detection process could be carried out in one tube. Specificity was demonstrated by detecting nucleic acid samples from pseudoviruses from seven human coronaviruses and Influenza A (H1N1). Clinical samples were used to validate the platform and all results were compared to rRT-PCR. RNA standards and pseudoviruses diluted by different gradients were used to demonstrate the detection limit. Additionally, we have developed a lateral flow assay based on OR-DETECTR for detecting COVID-19. RESULTS: The OR-DETECTR detection process can be completed in one tube, which takes approximately 50 min. This method can specifically detect SARS-CoV-2 from seven human coronaviruses and Influenza A (H1N1), with a low detection limit of 2.5 copies/µl input (RNA standard) and 1 copy/µl input (pseudovirus). Results of six samples from SARS-CoV-2 patients, eight samples from patients with fever but no SARS-CoV-2 infection, and one mixed sample from 40 negative controls showed that OR-DETECTR is 100% consistent with rRT-PCR. The lateral flow assay based on OR-DETECTR can be used for the detection of COVID-19, and the detection limit is 2.5 copies/µl input. CONCLUSIONS: The OR-DETECTR platform for the detection of COVID-19 is rapid, accurate, tube closed, easy-to-operate, and free of large instruments.
format Online
Article
Text
id pubmed-7884969
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78849692021-02-16 One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a Sun, Yangyang Yu, Lei Liu, Chengxi Ye, Shanting Chen, Wei Li, Dechang Huang, Weiren J Transl Med Research BACKGROUND: COVID-19 has spread rapidly around the world, affecting a large percentage of the population. When lifting certain mandatory measures for an economic restart, robust surveillance must be established and implemented, with nucleic acid detection for SARS-CoV-2 as an essential component. METHODS: We tried to develop a one-tube detection platform based on RT-RPA (Reverse Transcription and Recombinase Polymerase Isothermal Amplification) and DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR) technology, termed OR-DETECTR, to detect SARS-CoV-2. We designed RT-RPA primers of the RdRp and N genes following the SARS-CoV-2 gene sequence. We optimized reaction components so that the detection process could be carried out in one tube. Specificity was demonstrated by detecting nucleic acid samples from pseudoviruses from seven human coronaviruses and Influenza A (H1N1). Clinical samples were used to validate the platform and all results were compared to rRT-PCR. RNA standards and pseudoviruses diluted by different gradients were used to demonstrate the detection limit. Additionally, we have developed a lateral flow assay based on OR-DETECTR for detecting COVID-19. RESULTS: The OR-DETECTR detection process can be completed in one tube, which takes approximately 50 min. This method can specifically detect SARS-CoV-2 from seven human coronaviruses and Influenza A (H1N1), with a low detection limit of 2.5 copies/µl input (RNA standard) and 1 copy/µl input (pseudovirus). Results of six samples from SARS-CoV-2 patients, eight samples from patients with fever but no SARS-CoV-2 infection, and one mixed sample from 40 negative controls showed that OR-DETECTR is 100% consistent with rRT-PCR. The lateral flow assay based on OR-DETECTR can be used for the detection of COVID-19, and the detection limit is 2.5 copies/µl input. CONCLUSIONS: The OR-DETECTR platform for the detection of COVID-19 is rapid, accurate, tube closed, easy-to-operate, and free of large instruments. BioMed Central 2021-02-16 /pmc/articles/PMC7884969/ /pubmed/33593370 http://dx.doi.org/10.1186/s12967-021-02741-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Yangyang
Yu, Lei
Liu, Chengxi
Ye, Shanting
Chen, Wei
Li, Dechang
Huang, Weiren
One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a
title One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a
title_full One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a
title_fullStr One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a
title_full_unstemmed One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a
title_short One-tube SARS-CoV-2 detection platform based on RT-RPA and CRISPR/Cas12a
title_sort one-tube sars-cov-2 detection platform based on rt-rpa and crispr/cas12a
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884969/
https://www.ncbi.nlm.nih.gov/pubmed/33593370
http://dx.doi.org/10.1186/s12967-021-02741-5
work_keys_str_mv AT sunyangyang onetubesarscov2detectionplatformbasedonrtrpaandcrisprcas12a
AT yulei onetubesarscov2detectionplatformbasedonrtrpaandcrisprcas12a
AT liuchengxi onetubesarscov2detectionplatformbasedonrtrpaandcrisprcas12a
AT yeshanting onetubesarscov2detectionplatformbasedonrtrpaandcrisprcas12a
AT chenwei onetubesarscov2detectionplatformbasedonrtrpaandcrisprcas12a
AT lidechang onetubesarscov2detectionplatformbasedonrtrpaandcrisprcas12a
AT huangweiren onetubesarscov2detectionplatformbasedonrtrpaandcrisprcas12a